Skip to content

A randomised controlled trial to investigate the effectiveness of the healthy sexual functioning module and selective serotonin reuptake inhibitor medication to treat deviant sexual arousal as part of the HM prison sex offender treatment programme

A randomised controlled trial to investigate the effectiveness of the healthy sexual functioning module and selective serotonin reuptake inhibitor medication to treat deviant sexual arousal as part of the HM prison sex offender treatment programme

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN09267489
Enrollment
480
Registered
2006-06-07
Start date
2006-09-01
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deviant sexual arousal Mental and Behavioural Disorders Sex offender

Interventions

HSF evaluation: consenting eligible subjects will be randomised to either treatment with the HSF module (receiving treatment in the next available treatment slot) or a waiting list control group (rece

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Consent to treatment in HSF module of HM prison sex offender treatment programme with written informed consent. In addition, for SSRI sub-study, any one of the following: 1. Sexual preoccupation (either from clinical assessment or based on the multiphasic sex inventory [MSI] obsession scale) 2. A compulsive aspect to their offending (based on clinical judgement) 3. Mood state being an important contributor to their offending (based on clinical judgement) 4. Impulsivity (based on clinical judgement or impulsivity score)

Exclusion criteria

Exclusion criteria: HSF evaluation: urgent treatment need as assessed by the treatment manager SSRI sub-study only: 1. Presence of psychotic disorder or major mood disorder, epilepsy, uncontrolled seizure disorders, diabetes, major cardiac problems or severe renal failure. 2. Concomitant treatment with psychoactive medication which may interact with the effects of the SSRI e.g. neuroleptic or antidepressant medication 3. Concomitant treatment with an anti-androgen 4. Concomitant treatment with an anti-coagulant 5. Current treatment, or treatment within the last 4 weeks with SSRI 6. Previous adverse reaction to an SSRI

Design outcomes

Primary

MeasureTime frame
The multiphasic sex inventory - sexual obsessions sub-scale

Secondary

MeasureTime frame
HSF: penile plethysmography and impulsivity scale (sex offender treatment programme) SSRI only: 1. Fantasy visual analogue scale 2. Sexual outlet inventory 3. Yale-brown obsessive-compulsive scale 4. Hospital anxiety and depression scale 5. Mood visual analogue scale and Udvalg for Kliniske Undersogelser (UKU) side effect rating

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026